Expand AMGN Menu
AMGN MENU

AMGN Latest Press Releases

-- February 18, 2025 --

GeminiBio Appoints Mike Stella to Board Business Wire 9:00 AM

-- February 14, 2025 --

AMGEN TO PRESENT AT CITI'S 2025 VIRTUAL ONCOLOGY LEADERSHIP SUMMIT PRNewswire 4:01 PM

-- February 7, 2025 --

AMGEN TO PRESENT AT THE 35th ANNUAL OPPENHEIMER HEALTHCARE LIFE SCIENCES CONFERENCE PRNewswire 4:01 PM

-- February 4, 2025 --

AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS PRNewswire 4:01 PM

-- January 31, 2025 --

AMGEN ANNOUNCES WEBCAST OF 2024 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS PRNewswire 6:30 PM

-- January 22, 2025 --

deCODE genetics: Complete recombination map of the human-genome, a major step in genetics PRNewswire 11:00 AM

-- January 17, 2025 --

FDA APPROVES LUMAKRAS (SOTORASIB) IN COMBINATION WITH VECTIBIX (PANITUMUMAB) FOR CHEMOREFRACTORY KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER PRNewswire 9:01 AM

-- January 8, 2025 --

AMGEN TO PRESENT AT 43RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE PRNewswire 4:01 PM
Asher Bio Announces Clinical Trial Collaboration and Supply Agreement on Etakafusp Alfa (AB248) in Combination with Bispecific T-cell Engager in Patients with Small Cell Lung Cancer Business Wire 8:00 AM

-- December 10, 2024 --

AMGEN ANNOUNCES 2025 FIRST QUARTER DIVIDEND PRNewswire 4:30 PM

-- December 7, 2024 --

BLINCYTO (BLINATUMOMAB) ADDED TO CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN NEWLY DIAGNOSED PEDIATRIC PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) PRNewswire 10:00 AM

-- December 5, 2024 --

AMGEN ANNOUNCES $1 BILLION MANUFACTURING EXPANSION IN NORTH CAROLINA PRNewswire 9:00 AM

-- December 2, 2024 --

AMGEN TO PRESENT AT CITI'S 2024 GLOBAL HEALTHCARE CONFERENCE PRNewswire 4:00 PM

-- November 29, 2024 --

AMGEN TO PRESENT AT THE 7th ANNUAL EVERCORE HEALTHCONx CONFERENCE PRNewswire 4:30 PM

-- November 26, 2024 --

AMGEN ANNOUNCES ROBUST WEIGHT LOSS WITH MARITIDE IN PEOPLE LIVING WITH OBESITY OR OVERWEIGHT AT 52 WEEKS IN A PHASE 2 STUDY PRNewswire 7:05 AM
AMGEN TO HOST WEBCAST TO DISCUSS MARITIDE PHASE 2 RESULTS AND PROGRESS ON DEVELOPMENT PROGRAM PRNewswire 7:00 AM

-- November 20, 2024 --

AMGEN ANNOUNCES SENIOR EXECUTIVE RESEARCH APPOINTMENT PRNewswire 4:00 PM

-- November 15, 2024 --

AMGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Amgen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm Globe Newswire 9:00 PM

-- November 14, 2024 --

AMGEN PRESENTS NEW DATA ACROSS RARE INFLAMMATORY DISEASES AT ACR 2024 PRNewswire 4:00 PM

-- November 13, 2024 --

MOORE LAW ENCOURAGES AMGEN INC. INVESTORS TO CONTACT LAW FIRM PRNewswire 3:27 PM
AMGEN PROVIDES STATEMENT ON MARITIDE PHASE 1 DATA PRNewswire 5:00 AM

-- November 8, 2024 --

AMGEN TO PRESENT AT THE 2024 UBS GLOBAL HEALTHCARE CONFERENCE PRNewswire 4:00 PM
TEZSPIRE MET BOTH CO-PRIMARY ENDPOINTS IN PHASE 3 TRIAL FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS PRNewswire 2:00 AM

-- October 30, 2024 --

AMGEN REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS PRNewswire 4:01 PM

-- October 25, 2024 --

AMGEN ANNOUNCES 2024 FOURTH QUARTER DIVIDEND PRNewswire 4:00 PM

-- October 24, 2024 --

AMGEN ANNOUNCES WEBCAST OF 2024 THIRD QUARTER FINANCIAL RESULTS PRNewswire 4:00 PM

-- October 15, 2024 --

AMGEN PRESENTS POSITIVE PHASE 3 DATA FOR UPLIZNA (INEBILIZUMAB-CDON) IN GENERALIZED MYASTHENIA GRAVIS (GMG) AT AANEM 2024 PRNewswire 8:00 AM

-- October 1, 2024 --

LA LA ANTHONY PARTNERS WITH AMGEN TO SHARE CANDID, BEHIND-THE-SCENES LOOK AT HOW PLAQUE PSORIASIS AFFECTS HER LIFE PRNewswire 9:00 AM

-- September 30, 2024 --

NASDAQ: AMGN Lawsuit Notice: Investors in shares of Amgen Inc. (NASDAQ: AMGN) should contact the Shareholders Foundation PRNewswire 10:30 AM

-- September 24, 2024 --

TEPEZZA (TEPROTUMUMAB) RECEIVES APPROVAL IN JAPAN FOR THE TREATMENT OF ACTIVE THYROID EYE DISEASE PRNewswire 4:00 PM

-- September 23, 2024 --

AMGEN TO HOST CONFERENCE CALL TO DISCUSS NEW TOPLINE DATA IN INFLAMMATION AND RARE DISEASE PRNewswire 4:00 PM